184 related articles for article (PubMed ID: 32334964)
1. Revisiting pharmacy-based naloxone with pharmacists and naloxone consumers in 2 states: 2017 perspectives and evolving approaches.
Green TC; Donovan E; Klug B; Case P; Baird J; Burstein D; Tapper A; Walley AY; Bratberg J
J Am Pharm Assoc (2003); 2020; 60(5):740-749. PubMed ID: 32334964
[TBL] [Abstract][Full Text] [Related]
2. Perpetuating stigma or reducing risk? Perspectives from naloxone consumers and pharmacists on pharmacy-based naloxone in 2 states.
Green TC; Case P; Fiske H; Baird J; Cabral S; Burstein D; Schwartz V; Potter N; Walley AY; Bratberg J
J Am Pharm Assoc (2003); 2017; 57(2S):S19-S27.e4. PubMed ID: 28214219
[TBL] [Abstract][Full Text] [Related]
3. Pharmacy leaders' beliefs about how pharmacies can support a sustainable approach to providing naloxone to the community.
Donovan E; Bratberg J; Baird J; Burstein D; Case P; Walley AY; Green TC
Res Social Adm Pharm; 2020 Oct; 16(10):1493-1497. PubMed ID: 31983625
[TBL] [Abstract][Full Text] [Related]
4. Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose.
Donovan E; Case P; Bratberg JP; Baird J; Burstein D; Walley AY; Green TC
J Urban Health; 2019 Jun; 96(3):367-378. PubMed ID: 30747371
[TBL] [Abstract][Full Text] [Related]
5. If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study.
Slocum S; Ozga JE; Joyce R; Walley AY; Pollini RA
BMC Public Health; 2022 Apr; 22(1):735. PubMed ID: 35418048
[TBL] [Abstract][Full Text] [Related]
6. Pharmacy naloxone codispensing: A mixed methods study of practices and perspectives under a statewide standing order program.
Pollini RA; Slocum S; Ozga JE; Joyce R; Xuan Z; Green TC; Walley AY
J Am Pharm Assoc (2003); 2022; 62(5):1546-1554. PubMed ID: 35450833
[TBL] [Abstract][Full Text] [Related]
7. "Like it was just everyday business": A qualitative study of pharmacy-based naloxone and syringe customer experience.
Gray M; Shin SS; Silcox J; Flores D; Bolivar D; Irwin AN; Floyd AS; Bratberg J; Boggis JS; Hartung DM; Green TC
J Am Pharm Assoc (2003); 2023; 63(3):838-846. PubMed ID: 36872182
[TBL] [Abstract][Full Text] [Related]
8. Pharmacists and Naloxone: Barriers to Dispensing and Effectiveness of an Educational Outreach Program.
Hanson KA; Smart MH; Mandava MR; Carkovic E; Aslamy M; Lee TA; Pickard AS
J Am Pharm Assoc (2003); 2023; 63(2):608-613.e3. PubMed ID: 36631342
[TBL] [Abstract][Full Text] [Related]
9. Pharmacy on-site overdose protocols and prevention of overdose.
Green TC; Soipe A; Baloy B; Burstein D; Xuan Z; Tapper A; Walley AY; Case P; Bratberg J; Baird J
Subst Abus; 2022; 43(1):64-68. PubMed ID: 32186478
[TBL] [Abstract][Full Text] [Related]
10. Pharmacist attitudes toward pharmacy-based naloxone: A cross-sectional survey study.
Burstein D; Baird J; Bratberg J; Donovan E; Soipe A; Tapper A; Case P; Walley AY; Green TC
J Am Pharm Assoc (2003); 2020; 60(2):304-310. PubMed ID: 31870862
[TBL] [Abstract][Full Text] [Related]
11. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
[TBL] [Abstract][Full Text] [Related]
12. Pharmacists' naloxone services beyond community pharmacy settings: A systematic review.
Rawal S; Osae SP; Cobran EK; Albert A; Young HN
Res Social Adm Pharm; 2023 Feb; 19(2):243-265. PubMed ID: 36156267
[TBL] [Abstract][Full Text] [Related]
13. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone.
Green TC; Dauria EF; Bratberg J; Davis CS; Walley AY
Harm Reduct J; 2015 Aug; 12():25. PubMed ID: 26245865
[TBL] [Abstract][Full Text] [Related]
14. "I go out of my way to give them an extra smile now:" A study of pharmacists who participated in Respond to Prevent, a community pharmacy intervention to accelerate provision of harm reduction materials.
Irwin AN; Gray M; Ventricelli D; Boggis JS; Bratberg J; Floyd AS; Silcox J; Hartung DM; Green TC
Res Social Adm Pharm; 2024 May; 20(5):512-519. PubMed ID: 38395644
[TBL] [Abstract][Full Text] [Related]
15. Why aren't Australian pharmacists supplying naloxone? Findings from a qualitative study.
Olsen A; Lawton B; Dwyer R; Taing MW; Chun KLJ; Hollingworth S; Nielsen S
Int J Drug Policy; 2019 Jul; 69():46-52. PubMed ID: 31078908
[TBL] [Abstract][Full Text] [Related]
16. Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.
Green TC; Bratberg J; Irwin AN; Boggis J; Gray M; Leichtling G; Bolivar D; Floyd A; Al-Jammali Z; Arnold J; Hansen R; Hartung D
Subst Abus; 2022; 43(1):901-905. PubMed ID: 35213293
[TBL] [Abstract][Full Text] [Related]
17. Assessing pharmacists' readiness to dispense naloxone and counsel on responding to opioid overdoses.
Melaragni F; Levy C; Pedrazzi J; Andersen M
J Am Pharm Assoc (2003); 2019; 59(4):550-554.e2. PubMed ID: 31109812
[TBL] [Abstract][Full Text] [Related]
18. Pharmacists' experiences with a statewide naloxone standing order program in Massachusetts: a mixed methods study.
Pollini RA; Slocum S; Ozga J; Joyce R; Xuan Z; Green TC; Walley AY
J Am Pharm Assoc (2003); 2022; 62(1):157-166. PubMed ID: 34511372
[TBL] [Abstract][Full Text] [Related]
19. Naloxone Co-Dispensing with Opioids: a Cluster Randomized Pragmatic Trial.
Binswanger IA; Rinehart D; Mueller SR; Narwaney KJ; Stowell M; Wagner N; Xu S; Hanratty R; Blum J; McVaney K; Glanz JM
J Gen Intern Med; 2022 Aug; 37(11):2624-2633. PubMed ID: 35132556
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of naloxone furnishing community pharmacies in San Francisco.
Nguyen AM; Kearney TE; Apollonio DE
J Am Pharm Assoc (2003); 2020; 60(6):1050-1057.e1. PubMed ID: 32948461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]